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Abstract  
Infections caused by beta-lactamases producing Gram-negative bacteria are increasing, thus 
posing a challenge to the management of such infections. The surveillance data of such bacteria 
is limited in Nepal so this study aimed to detect the beta-lactamase producing Gram-negative 
bacteria in a tertiary setting. A total of 604 clinical samples, including urine, blood, sputum and 
body fluids, were cultured and identified by the routine standard laboratory protocols. 
Antibiotic susceptibility testing was done by Kirby Bauer disc diffusion method following 
Clinical and Laboratory Standard Institute guidelines (2014). Extended-spectrum beta-
lactamases (ESBL) producers were identified by combined disk method and metallo-beta-
lactamases (MBL) producers were identified by Imipenem- EDTA combined disk method. Out 
of 604 samples, 282 (46.7%) samples showed significant growth, of which 229 (81.2%) were Gram-
negative bacteria. Of 229 Gram-negative bacteria, 200 (87.3%) were multidrug resistant, 67 
(29.3%) were ESBL producers and 16 (7.0%) were MBL producers. Klebsiella pneumoniae were 
among higher ESBL producers and Pseudomonas aeruginosa were among higher MBL producers. 
The findings suggest higher antibacterial resistance among Gram-negative bacteria with the 
added burden of beta-lactamase production. Imipenem was effective against 125 of 229 Gram-
negative bacteria tested. Thus, imipenem can be the drug of choice for empirical management. 
The higher multidrug resistance and higher beta-lactamases production among Gram-negative 
bacteria warrant the continuous monitoring, surveillance, early detection, and infection control 
practices of such bacteria. 
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Introduction 
Antibacterial resistance (ABR) is an 
increasingly serious threat to human health, 
challenging the effective management of 
infections. ABR increase the health care cost as 
a result of prolonged illness, additional tests 
and pricier drugs [1]. Annually, more than 
750,000 deaths are caused by resistant bacteria. 
The median overall increased cost to treat a 
resistant bacterial infection is around 700 USD 
[2]. 
ABR is a natural genetic change, thus newer 
mechanisms are emerging and spreading, 
raising multidrug-resistant (MDR) bacteria [1]. 
One of the most worrisome resistance 
mechanisms is the production of beta-
lactamases, of which extended-spectrum beta-
lactamases (ESBLs) and metallo-beta-
lactamases (MBLs) are the most impacting 
ones. ESBLs can hydrolyze all beta-lactam 
antibiotics including cephalosporins except 
cephamycins or carbapenems [3]. ESBLs are 
often plasmid-mediated. Since it was first 
reported from Germany in 1983, it has then 
spread worldwide [4]. In Nepal, ESBLs were 
first reported in 2006 [5]. Similarly, MBLs can 
hydrolyze all broad-spectrum beta-lactams 
including cephalosporins, and carbapenems, 
except monobactams [6]. Since its first report 
from Japan in 1991, it has also been reported 
Nepal Journal of Biotechnology. Dec .  2019  Vol. 7, No. 1: 74-81                  Maharjan et al. 2019 
 
©NJB, Biotechnology Society of Nepal  75 Nepjol.info/index.php/njb. 
 
 
worldwide [7]. MBLs were first reported in 
Nepal in 2009 [8]. 
The acquisition, expression, and dissemination 
of beta-lactamase producing genes in 
pathogens have posed the major public health 
concern today [9]. Limited data are available on 
surveilling beta-lactamase producing clinical 
isolates in Nepal. ABR surveillance data can 
guide the physician in choosing appropriate 
therapy for effective management of infectious 
disease without extensive testing. Thus, this 
study aimed to produce updated data on 
surveilling beta-lactamase producing clinical 
isolates in a tertiary healthcare setting. This 
would help to formulate antimicrobial 
stewardship policy to circumvent the rising 
threat of ABR. 
Materials and Methods 
Study setting, design and study 
population 
A prospective hospital-based study was 
conducted in the Department of Microbiology 
at Annapurna Neurological Institute and 
Applied Science, Kathmandu, Nepal from 
March to November 2014. A total of 604 clinical 
samples from patients of all ages and both 
sexes, visiting the hospital and requesting a 
routine investigation, was included in the 
study. The samples include 263 urines (clean 
catch urine and catheter tip), 140 sputum 
samples, 73 blood samples and 128 body fluids 
(pus, pus swab, CSF, bile fluid, pleural fluid, 
peritoneal fluid, synovial fluid, and tracheal 
secretion). Contaminated samples and 
repeated samples from the same patient were 
excluded to avoid selection bias.  
Laboratory processing of the samples 
The samples were subjected to the standard 
microbiological procedures for isolation and 
identification of bacteria. In short, the samples 
were inoculated onto MacConkey agar 
(HiMedia, India) and blood agar (HiMedia, 
India) plate by streaking, followed by 
incubation at 37℃. Growths of bacteria were 
observed after 18-48hrs. The identification of 
Gram-negative bacteria was done by Gram’s 
stain morphology, cultural characteristics, and 
conventional biochemical tests. Biochemical 
tests employed were catalase test, oxidase test, 
indole test, citrate utilization test, methyl red 
test, Voges-Proskauer test, Christensen’s 
urease test, triple sugar iron test, decarboxylase 
test, and phenylalanine deaminase test. 
Antimicrobial susceptibility testing 
The antimicrobial susceptibility test of all 
identified bacteria against antibiotics of various 
classes was done in vitro by Kirby-Bauer disc 
diffusion method [10]. A zone of inhibitions 
(ZOI) for each disc was measured and the 
results were interpreted as per CLSI guideline 
M100-S24 [11]. Control strains Escherichia coli 
ATCC 25922 and Pseudomonas aeruginosa ATCC 
27853 were used for the quality control of the 
test. 
Detection of extended-spectrum beta-
lactamase producing strain 
ESBL producing isolates were identified by a 
phenotypic method as described in CLSI 
guideline M100-S24 [11]. 
Screening test for ESBL:  
Isolates exhibiting resistance against 
ceftriaxone (30µg) (ZOI ≤25mm) and/or 
ceftazidime (30µg) (ZOI ≤22mm) and/or 
cefpodoxime (10µg) (ZOI ≤17mm) and/or 
cefotaxime (30µg) (ZOI ≤27mm) were screened 
for ESBL production. 
Combined disc (CD) method as a 
confirmatory test for ESBL:  
ZOIs of isolates against ceftazidime disc (30µg) 
and cefotaxime (30µg) were compared against 
ZOIs of isolates against ceftazidime disc (30µg) 
containing clavulanic acid (10µg) and 
cefotaxime (30µg) containing clavulanic acid 
(10µg) when placed 25mm apart (center to 
center). The isolates showing the difference of 
5mm or more between either of the two ZOIs of 
the disc and clavulanate added disc was 
confirmed positive for ESBL production. 
Klebsiella pneumoniae ATCC 700603 (ESBL 
positive) was used as control strains. 
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Table 1. Sample and significant growth pattern 
 Total samples Culture positive 
Gram-negative 
bacteria 
Gram-positive bacteria 
Gender (M: F ratio=1.45:1) 
Male 357 (59.1%) 174 (61.7%) 143 (62.4%) 31 (58.5%) 
Female 247 (40.9%) 108 (38.3%) 86 (37.6%) 22 (41.5%) 
Departments of patients 
Inpatients 471 (78%) 180 (63.8%) 157 (68.6%) 23 (76.7%) 
Outpatients 133 (22%) 102 (36.2%) 72 (31.4%) 30 (56.6%) 
Age groups (years): Infants and children, adolescents, adults, elders 
≤9 19 (3.2%) 3 (1.1%) 2 (0.9%) 1 (1.9%) 
10-19 56 (9.3%) 29 (10.3%) 26 (11.4%) 3 (5.7%) 
20-59 313 (51.8%) 129 (45.7%) 99 (43.2%) 30 (56.6%) 
≥60 216 (35.8%) 121 (42.9%) 102 (44.5%) 19 (35.8%) 
Total 604 (100%) 282 (100%) 229 (100%) 53 (100%) 
Detection of metallo-beta-lactamase 
producing strain 
Since during the study no standard protocol 
was available for the detection of MBL, MBL 
producing isolates were identified by the 
commonly used phenotypic method. 
Screening test for MBL: 
Isolates exhibiting resistance against 
ceftazidime (30µg) (ZOI<18mm) were screened 
for MBL production. The resistance against 
imipenem (10μg) and/or meropenem (10μg) 
was not used as a screening tool so as to avoid 
missing the detection of hidden MBL in 
bacteria. Bacterial suspension equivalent to 1:10 
dilution of 0.5 McFarland was used for lawn 
culture in Mueller-Hinton agar before 
incorporating antibiotic discs [12]. 
Combined disc (CD) method as a 
confirmatory test for MBL: 
ZOI of isolate against imipenem disc (10 µg) 
was compared against ZOI of isolates against 
imipenem disc (10µg) containing 292µg (10µl of 
0.1M) ethylenediamine-tetraacetic acid (EDTA) 
when placed 25mm apart (center to center). The 
isolates showing difference of 4mm or more 
between two ZOIs was confirmed positive for 
MBL production [12, 13]. P. aeruginosa ATCC 
27853 (MBL negative) and P. aeruginosa PA 
105663 (MBL positive) was used as control 
strains. 
Results 
Distribution of samples and isolates 
Of 604 samples, only 282 (46.7%) were culture 
positive. Higher number of samples from males 
were culture positive 174 (61.7%). Similarly, a 
higher number of samples from the inpatient 
department were culture positive, 180 (63.8%). 
Culture positivity increased with the age of 
patients. Among 282 culture positive, 229 
(81.2%) were Gram-negative bacteria (Table 1). 
Eight different species of Gram-negative 
bacteria were identified. Among these, E. coli 
were the predominant, 78 (34.1%). E. coli was 
also predominant in urine samples, 61(55.0%) 
(Table 2). 
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 Antibiotic susceptibility of Gram-
negative bacteria 
Of 229 Gram-negative bacteria, E. coli showed 
higher resistance against ampicillin, 
cefpodoxime, ceftriaxone, and cefixime, while 
imipenem and chloramphenicol were found 
effective. P. aeruginosa showed higher 
resistance against cefixime and cefpodoxime, 
while imipenem was found effective. Similarly, 
other Gram-negative bacteria showed higher 
resistance against ampicillin, cefpodoxime, and 
ceftriaxone, while imipenem was found fairly 
effective (Table 3). 
Distribution of beta-lactamase 
producers 
Of 229 Gram-negative bacteria, 200 (87.3%) 
were found MDR. Of these bacteria, 67 (29.3%) 
were ESBL producers and 16 (7.0%) were MBL 
producers. ESBL production was higher among 
sputum isolates i.e. 35 (52.2%) and MBL 
production was higher among urine isolates i.e. 
8 (50%) (Table 4).Distribution of beta-
lactamase production among Gram-negative 
bacteria 
Of 229 Gram-negative bacteria, MDR was 
found higher among Klebsiella spp. isolates. 
ESBL production was higher among K. 
pneumoniae 25 (37.3%), E. coli 16 (23.9%) and P. 
aeruginosa 16 (23.9%). Similarly, MBL 
production was higher among P. aeruginosa 9 
(56.3%) and E. coli 3 (18.8%) (Table 5). 
Discussion 
Rise of beta-lactamases among pathogens has 
now been a prime threat to global health. Beta-
lactamase production has been reported in P. 
aeruginosa, Acinetobacter spp. and 
Enterobacteriaceae [14]. The evidence has 
shown that ABR has a significant adverse 
impact on clinical outcomes and increases costs 
due to the consumption of health care resources 
[15]. Of 229 Gram-negative bacteria, 29.3% 
were found ESBL producers. Similar results 
were reported by previous studies as 25% in 
2013 [16], 25.8% in 2014 [17], 24% in 2015 [18], 
26.9% in 2015 [19] and 34.5% in 2017 [20]. ESBL 
producers are increasingly disseminating in 
Nepal, 0.6% in 2006 to 40% in 2017 [5, 16-22].  
ESBL production was higher among K. 
pneumoniae (37.3%), E. coli (23.9%) and P. 
aeruginosa (23.9%). 
Table 2: Distribution of Gram-negative bacteria in different clinical samples 
Bacteria Sample Total 
Urine Blood Sputum Body Fluid 
ACB* 2 (1.8%) 0 (0%) 4 (5.5%) 2 (4.9%) 8 (3.5%) 
Citrobacter spp. 1 (0.9%) 0 (0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 
E. coli 61 (55.0%) 0 (0%) 9 (12.3%) 8 (19.5%) 78 (34.1%) 
K. pneumoniae 16 (14.4%) 0 (0%) 33 (45.2%) 22 (53.7%) 71 (31.0%) 
K. oxytoca 15 (13.5%) 0 (0%) 6 (8.2%) 1 (2.4%) 22 (9.6%) 
P. aeruginosa 12 (10.8%) 2 (50%) 20 (27.4%) 7 (17.1%) 41 (17.9%) 
Proteus spp. 4 (3.6%) 0 (0%) 1 (1.4%) 1 (2.4%) 6 (2.6%) 
Salmonella spp. 0 (0.0%) 2 (50%) 0 (0.0%) 0 (0.0%) 2 (0.9%) 
Total 111 (100%) 4 (100%) 73 (100%) 41 (100%) 229(100%) 
*Acinetobacter calcoaceticus-baumannii Complex 
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Similar results were reported in E. coli as 25.8% 
by Pokhrel et al in 2014 [17], 22.4% by Raut et al 
in 2015 [23], 26.9% Yadav et al in 2015 [19]. 
Similarly, comparable results were reported in 
K. pneumoniae as 22.4% by Raut et al in 2015 [23] 
and 43.3% Nepal et al in 2017 [22]. ESBL 
production was higher among sputum isolates 
i.e. 35 (52.2%).  
Of 229 Gram-negative bacteria, 7% were found 
MBL producers. Similar results were reported 
by previous studies as 7.1% Khanal et al in 2013 
[16], 3.2% Pokhrel et al in 2014 [17] and 4% 
Nepal et al in 2017 [20]. But a lower rate of 1.3% 
was reported by Mishra et al in 2012 [12] and a 
higher rate of 15% was reported Ansari et al in 
2015 [18]. MBL producers are increasingly 
disseminating in Nepal [12, 16-18, 20]. MBL 
production was higher among P. aeruginosa 
isolates, 56.3%. Besides P. aeruginosa and 
Acinetobacter spp., MBL production was also 
found in E. coli and K. pneumoniae as well. MBL 
in Enterobacteriaceae was reported by similar 
studies reported [16-18, 20].  
However, this contrast with the result of similar 
previous studies [12] which reported MBL 
production only in P. aeruginosa and 
Acinetobacter spp. MBL production was higher 
among urine isolates i.e. 50% of total MBL 
producers. 
Genotypic methods are considered superior 
tools for surveillance of such ESBL and MBL 
producers. But the evolution of newer beta-
Table 3: Antibiotic susceptibility of Gram-negative bacteria 
Antibiotics E. coli (n=78) (%) P. aeruginosa (n=41) (%) Other GNB (n=110) (%) 
S I R S I R S I R 
Amikacin 30.8 14.1 55.1 58.5 17.1 24.4 39.1 11.8 49.1 
Ampicillin 5.1 0.0 94.9 12.2 0.0 87.8 4.5 0.9 94.5 
Aztreonam 10.3 15.4 74.4 34.1 19.5 46.3 20.0 10.0 70.0 
Ceftriaxone 5.1 2.6 92.3 19.5 0.0 80.5 5.5 0.9 93.6 
Cefixime 2.6 5.1 92.3 2.4 0.0 97.6 8.2 0.0 91.8 
Cefotaxime 3.8 7.7 88.5 17.1 2.4 80.5 10.0 0.9 89.1 
Cefpodoxime 5.1 0.0 94.9 12.2 0.0 87.8 5.5 0.0 94.5 
Ceftazidime 9.0 2.6 88.5 17.1 4.9 78.0 10.0 0.9 89.1 
Ciprofloxacin 14.1 1.3 84.6 19.5 2.4 78.0 11.8 0.0 88.2 
Chloramphenicol 38.5 9.0 52.6 58.5 17.1 24.4 30.9 18.2 50.9 
Co-trimoxazole 11.5 2.6 85.9 14.6 0.0 85.4 11.8 2.7 85.5 
Gentamicin 21.8 5.1 73.1 41.5 4.9 53.7 20.9 2.7 76.4 
Imipenem 39.7 15.4 44.9 78.0 0.0 22.0 56.4 4.5 39.1 
Nitrofurantoin 18.0 4.9 77.1 NT NT NT NT NT NT 
Norfloxacin 12.8 1.3 85.9 9.8 4.9 85.4 13.6 0.0 86.4 
Piperacillin/ 
Tazobactam 
NT NT NT 63.4 9.8 26.8 NT NT NT 
*GNB=Gram-negative bacteria, S=sensitive, I=intermediate, R=resistance, NT=not tested 
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lactamase genes would make use of such tools 
tough, owing to the lack of primers. Moreover, 
using such expensive tools in resource lacking 
settings, like Nepal, would be a fairy tale 
scenario. A combined disc phenotypic method 
using imipenem and EDTA for MBL, 
ceftazidime/clavulanate or cefotaxime 
/clavulanate for ESBL offers a cheaper 
alternative. Also, phenotypic method proves not 
only the presence of beta-lactamases producing 
genes but also their expression. This method has 
been reported to have a sensitivity of 100% and 
specificity of 98%, thus reliable [12, 24]. 
Of 229 Gram-negative bacteria, E. coli showed 
higher resistance against ampicillin, 
cefpodoxime, ceftriaxone, and cefixime while 
imipenem and chloramphenicol were found 
effective. P. aeruginosa showed higher resistance 
against cefixime and cefpodoxime while 
imipenem was found effective. Similarly, other 
Gram-negative bacteria showed higher 
resistance against ampicillin, cefpodoxime, and 
ceftriaxone while imipenem was found fairly 
effective. Imipenem was found as an effective 
drug against most of the tested Gram-negative 
isolates. This concords with similar reports 
which reported imipenem as the most sensitive 
drug [25, 26]. 
As per the expert consensus, isolates resistant to 
two or more classes of antibiotics are considered 
MDR strains [27]. Of 229 Gram-negative 
bacteria, 87.3% of the isolates were found MDR 
strains. MDR was found higher among Klebsiella 
spp. isolates (93.5%). Similarly, 87.8% of P. 
aeruginosa and 50% of Acinetobacter spp. isolates 
were found MDR strains. Some studies reported 
higher MDR in these bacteria [16, 18, 20]. 
In our study, nearly all ESBL and MBL 
producers were MDR strains. This limits 
physicians with therapeutics for the 
management of infections. Such ESBL 
producing strains can be inhibited by the use of 
beta-lacatamase inhibitors like clavulanate, but 
MBL producers are resistance to these inhibitors 
and MBL inhibitors are yet to be trialed in 
human. The reserve drug for MDR Gram-
negative bacteria is emptied with the evolution 
of newer beta-lactamases. Colistin has always 
been the ultimate weapon in the fight against 
MDR superbugs in case all other therapeutic 
options fail. However, resistance against colistin 
has been reported in recent times, rendering our 
drug arsenal completely empty for such 
superbugs [28-30]. 
ABR is a crisis that must be managed with the 
utmost urgency to contain it. Such surveillance 
that generates updated data is required for the 
implementation of sound strategies and public 
health actions to contain ABR. ABR requires 
concerted cross-sectional action by governments 
Table 5. Distribution of Gram-negative isolates producing ESBL and MBL 
Bacteria Total isolates MDR bacteria ESBL producers MBL producers 
ACB* 8 4 4 (6.0%) 2 (12.5%) 
Citrobacter spp. 1 1 0 (0.0%) 0 (0.0%) 
E. coli 78 65 16 (23.9%) 3 (18.8%) 
K. oxytoca 22 21 5 (7.5%) 0 (0.0%) 
K. pneumoniae 71 66 25 (37.3%) 2 (12.5%) 
P. aeruginosa 41 36 16 (23.9%) 9 (56.3%) 
Proteus spp. 6 6 0 (0.0%) 0 (0.0%) 
Salmonella spp. 2 1 1 (1.5%) 0 (0.0%) 
Total 229 200 (100%) 67 (100%) 16 (100%) 
*Acinetobacter calcoaceticus-baumannii Complex 
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and society as a whole. Currently, ‘the global 
action plan on antimicrobial resistance-2015’, as 
formulated by WHO [31], must be implemented 
as envisioned to tackle the ABR. 
Conclusion 
The findings suggest higher MDR, ESBL, and 
MBL not only among P. aeruginosa and 
Acinetobacter spp. but also among 
Enterobacteriaceae family, including E. coli and K. 
pneumoniae. Imipenem showed promising 
sensitivity against most of the Gram-negative 
isolates, thus it can be the antibiotic of choice for 
management of such infections. Evolving beta-
lactamases against newer generation beta-
lactams have posed a serious threat to public 
health. Only the continuous monitoring, 
surveillance, early detection, and infection 
control practices can ensure the effective 
management of such resistant strains. 
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